| Year |
Citation |
Score |
| 2021 |
Cerne R, Lippa A, Poe MM, Smith JL, Jin X, Ping X, Golani LK, Cook JM, Witkin JM. GABAkines - Advances in the discovery, development, and commercialization of positive allosteric modulators of GABA receptors. Pharmacology & Therapeutics. 108035. PMID 34793859 DOI: 10.1016/j.pharmthera.2021.108035 |
0.487 |
|
| 2021 |
Arandelović J, Santrač A, Batinić B, Todorović L, Ahmed Khan MZ, Rashid F, Poe MM, Obradović A, Cook JM, Savić MM. Positive and Negative Selective Allosteric Modulators of α5 GABAA Receptors: Effects on Emotionality, Motivation, and Motor Function in the 5xFAD Model of Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 34657887 DOI: 10.3233/JAD-215079 |
0.467 |
|
| 2021 |
Golani LK, Platt DM, Rüedi-Bettschen D, Edwanker C, Huang S, Poe MM, Furtmüller R, Sieghart W, Cook JM, Rowlett JK. 8-Substituted Triazolobenzodiazepines: and Pharmacology in Relation to Structural Docking at the α1 Subunit-Containing GABA Receptor. Frontiers in Pharmacology. 12: 625233. PMID 33959005 DOI: 10.3389/fphar.2021.625233 |
0.538 |
|
| 2021 |
Rahman MA, Keck TM, Poe MM, Sharmin D, Cook JM, Fischer BD. Synergistic antihyperalgesic and antinociceptive effects of morphine and methyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate (MP-III-024): a positive allosteric modulator at α2GABA and α3GABA receptors. Psychopharmacology. PMID 33585961 DOI: 10.1007/s00213-021-05791-1 |
0.511 |
|
| 2020 |
Li G, Nieman AN, Mian MY, Zahn NM, Mikulsky BN, Poe MM, Methuku KR, Liu Y, Cook JM, Stafford DC, Arnold LA. A Structure-Activity Relationship Comparison of Imidazodiazepines Binding at Kappa, Mu, and Delta Opioid Receptors and the GABA Receptor. Molecules (Basel, Switzerland). 25. PMID 32854311 DOI: 10.3390/Molecules25173864 |
0.727 |
|
| 2020 |
Nieman AN, Li G, Zahn NM, Mian MY, Mikulsky BN, Hoffman DA, Wilcox TM, Kehoe AS, Luecke IW, Poe MM, Alvarez-Carbonell D, Cook JM, Stafford DC, Arnold LA. Targeting nitric oxide production in microglia with novel imidazodiazepines for non-sedative pain treatment. Acs Chemical Neuroscience. PMID 32511908 DOI: 10.1021/Acschemneuro.0C00324 |
0.738 |
|
| 2020 |
Tudeau L, Acuña MA, Albisetti GW, Neumann E, Ralvenius WT, Scheurer L, Poe M, Cook JM, Johannssen HC, Ulrich Zeilhofer H. Mice lacking spinal α2GABA receptors: Altered GABAergic neurotransmission, diminished GABAergic antihyperalgesia, and potential compensatory mechanisms preventing a hyperalgesic phenotype. Brain Research. 146889. PMID 32439345 DOI: 10.1016/J.Brainres.2020.146889 |
0.522 |
|
| 2019 |
Poe MM, Agabiti SS, Liu C, Li V, Teske KA, Hsiao CC, Wiemer AJ. Probing the Ligand-Binding Pocket of BTN3A1. Journal of Medicinal Chemistry. PMID 31268699 DOI: 10.1021/Acs.Jmedchem.9B00825 |
0.324 |
|
| 2019 |
Witkin JM, Cerne R, Davis PG, Freeman KB, do Carmo JM, Rowlett JK, Methuku KR, Okun A, Gleason SD, Li X, Krambis MJ, Poe M, Li G, Schkeryantz JM, Jahan R, et al. The α2,3-selective potentiator of GABA receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in rats. Pharmacology, Biochemistry, and Behavior. PMID 30825491 DOI: 10.1016/J.Pbb.2019.02.013 |
0.795 |
|
| 2018 |
Li G, Stephen MR, Kodali R, Zahn NM, Poe MM, Tiruveedhula VVNPB, Huber AT, Schussman MK, Qualmann K, Panhans CM, Raddatz NJ, Baker DA, Prevot TD, Banasr M, Sibille E, et al. Synthesis of chiral GABA receptor subtype selective ligands as potential agents to treat schizophrenia as well as depression. Arkivoc : Free Online Journal of Organic Chemistry. 2018: 158-182. PMID 32774192 DOI: 10.24820/Ark.5550190.P010.460 |
0.735 |
|
| 2018 |
Witkin JM, Smith JL, Ping X, Gleason SD, Poe MM, Li G, Jin X, Hobbs J, Schkeryantz JM, McDermott JS, Alatorre AI, Siemian JN, Cramer JW, Airey DC, Methuku KR, et al. Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABA receptors: Improved bioavailability enhances anticonvulsant efficacy. Neuropharmacology. 137: 332-343. PMID 29778948 DOI: 10.1016/J.Neuropharm.2018.05.006 |
0.753 |
|
| 2018 |
Methuku KR, Li X, Cerne R, Gleason SD, Schkeryantz JM, Tiruveedhula VVNPB, Golani LK, Li G, Poe MM, Rahman MT, Cook JM, Fisher JL, Witkin JM. An antidepressant-related pharmacological signature for positive allosteric modulators of α2/3-containing GABA receptors. Pharmacology, Biochemistry, and Behavior. PMID 29715490 DOI: 10.1016/J.Pbb.2018.04.009 |
0.751 |
|
| 2018 |
Xu NZ, Ernst M, Treven M, Cerne R, Wakulchik M, Li X, Jones TM, Gleason SD, Morrow D, Schkeryantz JM, Rahman MT, Li G, Poe MM, Cook JM, Witkin JM. Negative allosteric modulation of alpha 5-containing GABAA receptors engenders antidepressant-like effects and selectively prevents age-associated hyperactivity in tau-depositing mice. Psychopharmacology. PMID 29374303 DOI: 10.1007/S00213-018-4832-9 |
0.768 |
|
| 2018 |
Li G, Stephen MR, Kodali R, Zahn NM, Poe MM, Tiruveedhula VVNPB, Huber AT, Schussman MK, Qualmann K, Panhans CM, Raddatz NJ, Baker DA, Prevot TD, Banasr M, Sibille E, et al. Synthesis of chiral GABAA receptor subtype selective ligands as potential agents to treat schizophrenia as well as depression Arkivoc. 2018: 158-182. DOI: 10.24820/ark.5550190.p010.460 |
0.686 |
|
| 2017 |
Foust BJ, Poe MM, Lentini NA, Hsiao CC, Wiemer AJ, Wiemer DF. Mixed Aryl Phosphonate Prodrugs of a Butyrophilin Ligand. Acs Medicinal Chemistry Letters. 8: 914-918. PMID 28947936 DOI: 10.1021/Acsmedchemlett.7B00245 |
0.32 |
|
| 2017 |
Witkin JM, Cerne R, Wakulchik M, S J, Gleason SD, Jones TM, Li G, Arnold LA, Li JX, Schkeryantz JM, Methuku KR, Cook JM, Poe MM. Further evaluation of the potential anxiolytic activity of imidazo[1,5-a][1,4]diazepin agents selective for α2/3-containing GABAA receptors. Pharmacology, Biochemistry, and Behavior. PMID 28442369 DOI: 10.1016/J.Pbb.2017.04.009 |
0.75 |
|
| 2017 |
Forkuo GS, Nieman AN, Yuan NY, Kodali R, Yu OB, Zahn NM, Jahan R, Li G, Stephen MR, Guthrie ML, Poe MM, Hartzler BD, Harris TW, Yocum GT, Emala CW, et al. Alleviation of Multiple Asthmatic Pathologic Features with Orally Available and Subtype Selective GABAA Receptor Modulators. Molecular Pharmaceutics. PMID 28440659 DOI: 10.1021/Acs.Molpharmaceut.7B00183 |
0.767 |
|
| 2017 |
Schwienteck KL, Li G, Poe MM, Cook JM, Banks ML, Stevens Negus S. Abuse-related effects of subtype-selective GABAA receptor positive allosteric modulators in an assay of intracranial self-stimulation in rats. Psychopharmacology. PMID 28365836 DOI: 10.1007/S00213-017-4615-8 |
0.718 |
|
| 2017 |
Fischer BD, Schlitt RJ, Hamade BZ, Rehman S, Ernst M, Poe MM, Li G, Kodali R, Arnold LA, Cook JM. Pharmacological and antihyperalgesic properties of the novel α2/3 preferring GABAA receptor ligand MP-III-024. Brain Research Bulletin. PMID 28267561 DOI: 10.1016/J.Brainresbull.2017.03.001 |
0.775 |
|
| 2017 |
Shippy RR, Lin X, Agabiti SS, Li J, Zangari BM, Foust BJ, Poe MM, Hsiao CC, Vinogradova O, Wiemer DF, Wiemer AJ. Phosphinophosphonates and their tris-pivaloyloxymethyl prodrugs reveal a negatively cooperative butyrophilin activation mechanism. Journal of Medicinal Chemistry. PMID 28218845 DOI: 10.1021/Acs.Jmedchem.6B00965 |
0.308 |
|
| 2017 |
Lewter LA, Fisher JL, Siemian JN, Methuku KR, Poe MM, Cook JM, Li JX. Antinociceptive effects of a novel α2/α3-subtype selective GABAA receptor positive allosteric modulator. Acs Chemical Neuroscience. PMID 28150939 DOI: 10.1021/Acschemneuro.6B00447 |
0.564 |
|
| 2017 |
Kannampalli P, Babygirija R, Zhang J, Poe MM, Li G, M Cook J, Shaker R, Banerjee B, Sengupta JN. Neonatal Bladder Inflammation Induces Long-term Visceral pain and Altered Responses of Spinal Neurons in Adult Rats. Neuroscience. PMID 28126369 DOI: 10.1016/J.Neuroscience.2017.01.021 |
0.64 |
|
| 2016 |
Poe MM, Methuku KR, Li G, Verma AR, Teske KA, Stafford DC, Arnold LA, Cramer JW, Jones TM, Cerne R, Krambis MJ, Witkin JM, Jambrina E, Rehman S, Ernst M, et al. Synthesis and Characterization of a Novel γ-Aminobutyric Acid Type A (GABAA) Receptor Ligand That Combines Outstanding Metabolic Stability, Pharmacokinetics, and Anxiolytic Efficacy. Journal of Medicinal Chemistry. 59: 10800-10806. PMID 27933953 DOI: 10.1021/Acs.Jmedchem.6B01332 |
0.73 |
|
| 2016 |
Piantadosi SC, French BJ, Poe MM, Timić T, Marković BD, Pabba M, Seney ML, Oh H, Orser BA, Savić MM, Cook JM, Sibille E. Sex-Dependent Anti-Stress Effect of an α5 Subunit Containing GABAA Receptor Positive Allosteric Modulator. Frontiers in Pharmacology. 7: 446. PMID 27920723 DOI: 10.3389/Fphar.2016.00446 |
0.523 |
|
| 2016 |
Jahan R, Stephen MR, Forkuo GS, Kodali R, Guthrie ML, Nieman AN, Yuan NY, Zahn NM, Poe MM, Li G, Yu OB, Yocum GT, Emala CW, Stafford DC, Cook JM, et al. Optimization of substituted imidazobenzodiazepines as novel asthma treatments. European Journal of Medicinal Chemistry. 126: 550-560. PMID 27915170 DOI: 10.1016/J.Ejmech.2016.11.045 |
0.747 |
|
| 2016 |
Stamenić TT, Poe MM, Rehman S, Santrač A, Divović B, Scholze P, Ernst M, Cook JM, Savić MM. Ester to amide substitution improves selectivity, efficacy and kinetic behavior of a benzodiazepine positive modulator of GABAA receptors containing the α5 subunit. European Journal of Pharmacology. PMID 27639297 DOI: 10.1016/J.Ejphar.2016.09.016 |
0.576 |
|
| 2016 |
Yuan NY, Poe MM, Witzigmann C, Cook JM, Stafford D, Arnold LA. Characterization of GABAA receptor ligands with automated patch-clamp using human neurons derived from pluripotent stem cells. Journal of Pharmacological and Toxicological Methods. PMID 27544543 DOI: 10.1016/J.Vascn.2016.08.006 |
0.734 |
|
| 2016 |
Jonas O, Calligaris D, Methuku KR, Poe MM, Francois JP, Tranghese F, Changelian A, Sieghart W, Ernst M, Krummel DA, Cook JM, Pomeroy SL, Cima M, Agar NY, Langer R, et al. First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development. Journal of Biomedical Nanotechnology. 12: 1297-302. PMID 27319222 DOI: 10.1166/Jbn.2016.2262 |
0.521 |
|
| 2016 |
Forkuo GS, Guthrie ML, Yuan NY, Nieman AN, Kodali R, Jahan R, Yocum GT, Treven M, Stephen MR, Poe MM, Li G, Yu OB, Hartzler BD, Zahn NM, Ernst M, et al. Development of GABAA Receptor Subtype-Selective Imidazobenzodiazepines as Novel Asthma treatments. Molecular Pharmaceutics. PMID 27120014 DOI: 10.1021/Acs.Molpharmaceut.6B00159 |
0.787 |
|
| 2016 |
Heise C, Taha E, Murru L, Ponzoni L, Cattaneo A, Guarnieri FC, Montani C, Mossa A, Vezzoli E, Ippolito G, Zapata J, Barrera I, Ryazanov AG, Cook J, Poe M, et al. eEF2K/eEF2 Pathway Controls the Excitation/Inhibition Balance and Susceptibility to Epileptic Seizures. Cerebral Cortex (New York, N.Y. : 1991). PMID 27005990 DOI: 10.1093/Cercor/Bhw075 |
0.441 |
|
| 2015 |
Clayton T, Poe MM, Rallapalli S, Biawat P, Savić MM, Rowlett JK, Gallos G, Emala CW, Kaczorowski CC, Stafford DC, Arnold LA, Cook JM. A Review of the Updated Pharmacophore for the Alpha 5 GABA(A) Benzodiazepine Receptor Model. International Journal of Medicinal Chemistry. 2015: 430248. PMID 26682068 DOI: 10.1155/2015/430248 |
0.766 |
|
| 2015 |
Botta P, Demmou L, Kasugai Y, Markovic M, Xu C, Fadok JP, Lu T, Poe MM, Xu L, Cook JM, Rudolph U, Sah P, Ferraguti F, Lüthi A. Corrigendum: Regulating anxiety with extrasynaptic inhibition. Nature Neuroscience. 18: 1862. PMID 26605888 DOI: 10.1038/Nn1215-1862A |
0.414 |
|
| 2015 |
Botta P, Demmou L, Kasugai Y, Markovic M, Xu C, Fadok JP, Lu T, Poe MM, Xu L, Cook JM, Rudolph U, Sah P, Ferraguti F, Lüthi A. Regulating anxiety with extrasynaptic inhibition. Nature Neuroscience. PMID 26322928 DOI: 10.1038/Nn.4102 |
0.473 |
|
| 2015 |
Gallos G, Yocum GT, Siviski ME, Yim PD, Fu XW, Poe MM, Cook JM, Harrison N, Perez-Zoghbi J, Emala CW. Selective targeting of the α5-subunit of GABAA receptors relaxes airway smooth muscle and inhibits cellular calcium handling. American Journal of Physiology. Lung Cellular and Molecular Physiology. 308: L931-42. PMID 25659897 DOI: 10.1152/Ajplung.00107.2014 |
0.672 |
|
| 2015 |
Richetto J, Labouesse MA, Poe MM, Cook JM, Grace AA, Riva MA, Meyer U. Behavioral effects of the benzodiazepine-positive allosteric modulator SH-053-2'F-S-CH₃ in an immune-mediated neurodevelopmental disruption model. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 18. PMID 25636893 DOI: 10.1093/Ijnp/Pyu055 |
0.508 |
|
| 2015 |
Stamenic TT, Santrac A, Divovic B, Poe M, James CM, Savic MM. P.1.h.011 Effects of positive α5-selective modulation of GABAA receptors on amphetamine-induced hyperactivation European Neuropsychopharmacology. 25. DOI: 10.1016/S0924-977X(15)30342-4 |
0.446 |
|
| 2015 |
Rowlett J, Duke AN, Platt D, Namjoshi OA, Poe M, Tiruveedhula PB, Cook J. Evidence for sedative effects of benzodiazepines involving unexpected GABA A receptor subtypes Drug and Alcohol Dependence. 156: e194. DOI: 10.1016/J.Drugalcdep.2015.07.523 |
0.568 |
|
| 2015 |
Fischer BD, Kroll C, Poe M, Cook JM. Effects of HZ-166, a novel a2 and a3 subunit-containing GABAA receptor agonist, on inflammatory pain and operant behavior in mice Drug and Alcohol Dependence. 146: e278. DOI: 10.1016/J.Drugalcdep.2014.09.223 |
0.488 |
|
| 2014 |
Obradović ALj, Joksimović S, Poe MM, Ramerstorfer J, Varagic Z, Namjoshi O, Batinić B, Radulović T, Marković B, Roth BL, Sieghart W, Cook JM, Savić MM. Sh-I-048A, an in vitro non-selective super-agonist at the benzodiazepine site of GABAA receptors: the approximated activation of receptor subtypes may explain behavioral effects. Brain Research. 1554: 36-48. PMID 24472579 DOI: 10.1016/J.Brainres.2014.01.036 |
0.586 |
|
| 2014 |
Gill KM, Cook JM, Poe MM, Grace AA. Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia. Schizophrenia Bulletin. 40: 341-50. PMID 24464874 DOI: 10.1093/Schbul/Sbt236 |
0.482 |
|
| 2014 |
Obradović LA, Joksimović S, Poe MM, Timić T, Cook JM, Savić MM. Delayed behavioral effects of SH-I-048A, a novel nonselective positive modulator of GABAA receptors, after peripheral nerve injury in rats. Acta Veterinaria-Beograd. 64: 189-199. DOI: 10.2478/Acve-2014-0018 |
0.487 |
|
| 2014 |
Jonas O, Sengupta S, Calligaris D, Poe M, Methuku K, Francois JP, Cook J, Agar N, Pomeroy S, Langer R. ET-24 * A NOVEL TROJAN HORSE FOR IN-VIVO SENSITIVITY TESTING OF MEDULLOBLASTOMA THERAPIES Neuro-Oncology. 16: v84-v84. DOI: 10.1093/Neuonc/Nou255.24 |
0.544 |
|
| 2014 |
Stamenic TT, Joksimovic S, Milic M, Batinic B, Poe MM, Cook JM, Savic MM. P.1.j.011 Positive modulation at alpha5GABAA receptors is not beneficial for cognitive deficits induced by MK-801 in water maze in rats European Neuropsychopharmacology. 24. DOI: 10.1016/S0924-977X(14)70516-4 |
0.342 |
|
| 2014 |
Richetto J, Labouesse MA, Poe MM, Cook JM, Grace AA, Riva MA, Meyer U. Poster #M240 BEHAVIORAL EFFECTS OF THE NOVEL BENZODIAZEPINE POSITIVE ALLOSTERIC MODULATOR SH-053-2′F-S-CH3 IN AN IMMUNE-MEDIATED NEURODEVELOPMENTAL DISRUPTION MODEL Schizophrenia Research. 153: S277. DOI: 10.1016/S0920-9964(14)70790-X |
0.438 |
|
| 2014 |
Sawyer EK, Fischer B, Meng Z, Poe M, Namjoshi O, Cook J, Rowlett J. Role of α3GABAA receptor modulation in the anti-conflict effects of benzodiazepine-type drugs in monkeys Drug and Alcohol Dependence. 140: e196-e197. DOI: 10.1016/J.Drugalcdep.2014.02.548 |
0.536 |
|
| 2013 |
Drexler B, Zinser S, Huang S, Poe MM, Rudolph U, Cook JM, Antkowiak B. Enhancing the function of alpha5-subunit-containing GABAA receptors promotes action potential firing of neocortical neurons during up-states. European Journal of Pharmacology. 703: 18-24. PMID 23380687 DOI: 10.1016/J.Ejphar.2013.01.034 |
0.764 |
|
| 2013 |
Timic T, Joksimovic S, Obradovic A, Poe M, Biawat P, Ramerstorfer J, Roth B, Sieghart W, Cook J, Savic M. P.1.h.029 MK-801-induced hyperlocomotion in rats is affected by modulation of α5-containing GABAA receptors European Neuropsychopharmacology. 23: S259-S260. DOI: 10.1016/S0924-977X(13)70405-X |
0.541 |
|
| Show low-probability matches. |